Cited by 780Parkinson's Disease Mechanisms and TreatmentsCoffee research and impactsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease

Ross, G. Webster·2000·JAMA

DOI 10.1001/jama.283.20.2674

Open this paper in CoChat — free account

Abstract

CONTEXT: The projected expansion in the next several decades of the elderly population at highest risk for Parkinson disease (PD) makes identification of factors that promote or prevent the disease an important goal. OBJECTIVE: To explore the association of coffee and dietary caffeine intake with risk of PD. DESIGN, SETTING, AND PARTICIPANTS: Data were analyzed from 30 years of follow-up of 8004 Japanese-American men (aged 45-68 years) enrolled in the prospective longitudinal Honolulu Heart Program between 1965 and 1968. MAIN OUTCOME MEASURE: Incident PD, by amount of coffee intake (measured at study enrollment and 6-year follow-up) and by total dietary caffeine intake (measured at enrollment). RESULTS: During follow-up, 102 men were identified as having PD. Age-adjusted incidence of PD declined consistently with increased amounts of coffee intake, from 10.4 per 10,000 person-years in men who drank no coffee to 1.9 per 10,000 person-years in men who drank at least 28 oz/d (P<.001 for trend). Similar relationships were observed with total caffeine intake (P<.001 for trend) and caffeine from non-coffee sources (P=.03 for trend). Consumption of increasing amounts of coffee was also associated with lower risk of PD in men who were never, past, and current smokers at baseline (P=.049, P=.22, and P=.02, respectively, for trend). Other nutrients in coffee, including niacin, were unrelated to PD incidence. The relationship between caffeine and PD was unaltered by intake of milk and sugar. CONCLUSIONS: Our findings indicate that higher coffee and caffeine intake is associated with a significantly lower incidence of PD. This effect appears to be independent of smoking. The data suggest that the mechanism is related to caffeine intake and not to other nutrients contained in coffee. JAMA. 2000;283:2674-2679.

Integrity signals

Registry

Crossref · 10.1001/jama.283.20.2674

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Parkinson's Disease
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Epidemiology of parkinson’s disease
Tanner, C. M., & Goldman, S. M. (1996) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70259-0 · Cited by 640
Coffee, Alcohol and Risk of Coronary Heart Disease among Japanese Men Living in Hawaii
Yano, K., Rhoads, G. G., & Kagan, A. (1977) · New England Journal of Medicine · doi:10.1056/nejm197708252970801 · Cited by 524
Prevalence of Dementia in Older Japanese-American Men in Hawaii: The Honolulu-Asia Aging Study
White, L. (1996) · JAMA · doi:10.1001/jama.1996.03540120033030 · Cited by 437
TEN-YEAR INCIDENCE OF CORONARY HEART DISEASE IN THE HONOLULU HEART PROGRAM
Yano, K., REED, D. M., & McGee, D. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113787 · Cited by 370
Worldwide Occurrence of Parkinson's Disease: An Updated Review
Zhang, Z., & Román, G. C. (1993) · Neuroepidemiology · doi:10.1159/000110318 · Cited by 332

Show all 35 references

Sorted by citations

Items 101–200 of 780

Behavioural Risk Factors in Mid-Life Associated with Successful Ageing, Disability, Dementia and Frailty in Later Life: A Rapid Systematic Review
Lafortune, L., Martin, S., Kelly, S., Kuhn, I., Remes, O., Cowan, A., & Brayne, C. (2016) · PLOS ONE · doi:10.1371/journal.pone.0144405 · Cited by 165
Update on Parkinson Disease
Siderowf, A. D., & Stern, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00013 · Cited by 164
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease
Milber, J. M., Noorigian, J. V., Morley, J. F., Petrovitch, H., White, L., Ross, G. W., & Duda, J. E. (2012) · Neurology · doi:10.1212/wnl.0b013e318278fe32 · Cited by 163
Self-citation
Midlife adiposity and the future risk of Parkinson’s disease
Abbott, R. D., Ross, G. W., White, L. R., Nelson, J. S., Masaki, K., Tanner, C. M., Curb, J. D., Blanchette, P. L., Popper, J. S., & Petrovitch, H. (2002) · Neurology · doi:10.1212/wnl.59.7.1051 · Cited by 163
Self-citation
Sweetened beverages, coffee, and tea and depression risk among older US adults
Guo, X., Park, Y., Freedman, N. D., Sinha, R., Hollenbeck, A. R., Blair, A., & Chen, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094715 · Cited by 161
Plasma Urate and Parkinson's Disease in the Atherosclerosis Risk in Communities (ARIC) Study
Chen, H., Mosley, T. H., Alonso, Á., & Huang, X. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp033 · Cited by 161
Caffeinated clues and the promise of adenosine A2Aantagonists in PD
Schwarzschild, M. A., Chen, J., & Ascherio, A. (2002) · Neurology · doi:10.1212/wnl.58.8.1154 · Cited by 162
Effects of Caffeine in Parkinson's Disease: From Neuroprotection to the Management of Motor and Non-Motor Symptoms
Prediger, R. D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091459 · Cited by 172
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms
Yu, L., Shen, H., Coelho, J. E., Araújo, I. M., Huang, Q., Day, Y., Rebola, N., Canas, P. M., Rapp, E. K., Ferrara, J., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21313 · Cited by 170
Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease
Fuxé, K., Marcellino, D. J., Genedani, S., & Agnati, L. F. (2007) · Movement Disorders · doi:10.1002/mds.21440 · Cited by 159
Animal models for the study of adenosine receptor function
Yaar, R., Jones, M. R., Chen, J., & Ravid, K. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20138 · Cited by 160
Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells
Nakaso, K., Ito, S., & Nakashima, K. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.12.034 · Cited by 152
Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies
Wei, C. J., Li, W., & Chen, J. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.018 · Cited by 153
Effects of coffee on type 2 diabetes mellitus
Akash, M. S. H., Rehman, K., & Chen, S. (2013) · Nutrition · doi:10.1016/j.nut.2013.11.020 · Cited by 156
Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms
Ren, X., & Chen, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.602697 · Cited by 167
Evidence-based toxicology: a comprehensive framework for causation
Guzelian, P. S., Victoroff, M. S., Halmes, N. C., James, R. C., & Guzelian, C. P. (2005) · Human & Experimental Toxicology · doi:10.1191/0960327105ht517oa · Cited by 151
Caffeine and Its Antioxidant Properties—It Is All about Dose and Source
Ősz, B.-E., Jîtcă, G., Ștefănescu, R., Puşcaş, A., Tero-Vescan, A., & Vari, C.-E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113074 · Cited by 155
Consumption of milk and calcium in midlife and the future risk of Parkinson disease
Park, M., Ross, G. W., Petrovitch, H., White, L. R., Masaki, K., Nelson, J. S., Tanner, C. M., Curb, J. D., Blanchette, P. L., & Abbott, R. D. (2005) · Neurology · doi:10.1212/01.wnl.0000154532.98495.bf · Cited by 146
Self-citation
Diet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145
Lifestyle-related factors in predementia and dementia syndromes
Solfrizzi, V., Capurso, C. A., D’Introno, A., Colacicco, A. M., Santamato, A., Ranieri, M., Fiore, P., Capurso, A., & Panza, F. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.1.133 · Cited by 155
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk
Powers, K. M., Kay, D. M., Factor, S. A., Zabetian, C. P., Higgins, D. S., Samii, A., Nutt, J. G., Griffith, A., Leis, B. C., Roberts, J. W., et al. (2007) · Movement Disorders · doi:10.1002/mds.21782 · Cited by 144
Low plasma uric acid level in Parkinson's disease
Annanmäki, T., Muuronen, A., & Murros, K. E. (2007) · Movement Disorders · doi:10.1002/mds.21502 · Cited by 141
The Role of Extracellular Adenosine in Chemical Neurotransmission in the Hippocampus and Basal Ganglia: Pharmacological and Clinical Aspects
Sperlágh, B., & Vizi, E. S. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795347564 · Cited by 142
Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease
Xu, K., Xu, Y., Brown-Jermyn, D., Chen, J., Ascherio, A., Dluzen, D. E., & Schwarzschild, M. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3008-05.2006 · Cited by 145
Human monoamine oxidase enzyme inhibition by coffee and β-carbolines norharman and harman isolated from coffee
Herraiz, T., & Chaparro, C. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.074 · Cited by 144
Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
Iarkov, A., Barreto, G. E., Grizzell, J. A., & Echeverrı́a, V. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00004 · Cited by 146
The Promise of Neuroprotective Agents in Parkinson?s Disease
Seidl, S. E., & Potashkin, J. A. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00068 · Cited by 145
The personality associated with Parkinson’s disease
Menza, M. A. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0027-1 · Cited by 138
Adenosine Receptor Control of Cognition in Normal and Disease
Chen, J. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00012-x · Cited by 142
Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson??s Disease
Ross, G. W., & Petrovitch, H. (2001) · Drugs & Aging · doi:10.2165/00002512-200118110-00001 · Cited by 143
Self-citation
Epidemiologic studies of environmental exposures in Parkinson's disease
Elbaz, A., & Tranchant, C. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.06.024 · Cited by 141
Coffee Intake in Midlife and Risk of Dementia and its Neuropathologic Correlates
Gelber, R. P., Petrovitch, H., Masaki, K. H., Ross, G. W., & White, L. R. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101428 · Cited by 133
Self-citation
Caffeine Protects Against Disruptions of the Blood-Brain Barrier in Animal Models of Alzheimer's and Parkinson's Diseases
Chen, X., Ghribi, O., & Geiger, J. D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1376 · Cited by 137
Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease
Xu, K., Xu, Y.-H., Chen, J., & Schwarzschild, M. A. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.02.020 · Cited by 140
MPTP
Speciale, S. G. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00222-2 · Cited by 133
Caffeinated coffee, decaffeinated coffee, and the phenolic phytochemical chlorogenic acid up-regulate NQO1 expression and prevent H2O2-induced apoptosis in primary cortical neurons
Kim, J., Lee, S., Shim, J., Kim, H. W., Kim, J., Jang, Y. J., Yang, H. S., Park, J., Choi, S. H., Yoon, J. H., et al. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.02.004 · Cited by 133
Epidemiology of Parkinson's disease
Kasten, M., Chade, A., & Tanner, C. M. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83006-5 · Cited by 134
Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients
Mishina, M., Ishiwata, K., Naganawa, M., Kimura, Y., Kitamura, S., Suzuki, M., Hashimoto, M., Ishibashi, K., Oda, K., Sakata, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017338 · Cited by 136
Simultaneous electrochemical determination of dopamine, melatonin, methionine and caffeine
Molaakbari, E., Mostafavi, A., & Beitollahi, H. (2014) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2014.10.130 · Cited by 131
Defining at‐risk populations for Parkinson's disease: Lessons from ongoing studies
Berg, D., MAREK, K. L., Ross, G. W., & Poewe, W. H. (2012) · Movement Disorders · doi:10.1002/mds.24985 · Cited by 128
Self-citation
Potential Roles of Exosomes in Parkinson’s Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis
Yu, H., Sun, T., An, J., Wen, L., Liu, F., Bu, Z., Cui, Y., & Feng, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00086 · Cited by 130
Genetics of Parkinson disease
Pankratz, N., & Foroud, T. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e31815bf97c · Cited by 129
Coffee Induces Expression of Glucuronosyltransferases by the Aryl Hydrocarbon Receptor and Nrf2 in Liver and Stomach
Kalthoff, S., Ehmer, U., Freiberg, N., Manns, M. P., & Strassburg, C. P. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.048 · Cited by 124
Amiloride is neuroprotective in an MPTP model of Parkinson's disease
Arias, R. L., Sung, M.-L. A., Vasylyev, D. V., Zhang, M., Albinson, K., Kubek, K., Kagan, N., Beyer, C. E., Lin, Q., Dwyer, J. M., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.05.008 · Cited by 123
The Medicinal Chemistry of Caffeine
Faudone, G., Arifi, S., & Merk, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00261 · Cited by 133
A 2A adenosine receptor overexpression and functionality, as well as TNF‐α levels, correlate with motor symptoms in Parkinson's disease
Varani, K., Vincenzi, F., Tosi, A., Gessi, S., Casetta, I., Granieri, G., Fazio, P., Leung, E., MacLennan, S., Granieri, E., et al. (2009) · The FASEB Journal · doi:10.1096/fj.09-141044 · Cited by 121
The landscape of multiscale transcriptomic networks and key regulators in Parkinson’s disease
Wang, Q., Zhang, Y., Wang, M., Song, W.-M., Shen, Q., McKenzie, A., Choi, I., Zhou, X., Pan, P.-Y., Yue, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13144-y · Cited by 121
Adenosine A2A receptors in Parkinson’s disease treatment
Cieślak, M., Komoszyński, M., & Wojtczak, A. (2008) · Purinergic Signalling · doi:10.1007/s11302-008-9100-8 · Cited by 128
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease
Popat, R. A., Eeden, S. K. V. D., Tanner, C. M., Kamel, F., Umbach, D. M., Marder, K. S., Mayeux, R. P., Ritz, B. R., Ross, G. W., Petrovitch, H., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03353.x · Cited by 119
Self-citation
Pathological overproduction: the bad side of adenosine
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13763 · Cited by 118
8-(3-Chlorostyryl)caffeine May Attenuate MPTP Neurotoxicity through Dual Actions of Monoamine Oxidase Inhibition and A2A Receptor Antagonism
Chen, J., Steyn, S., Staal, R. G. W., Petzer, J. P., Xu, K., der Schyf, C. J. V., Castagnoli, K., Sonsalla, P. K., Castagnoli, N. J., & Schwarzschild, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206830200 · Cited by 116
Parkinson disease: etiology, pathogenesis and future of gene therapy
Shastry, B. S. (2001) · Neuroscience Research · doi:10.1016/s0168-0102(01)00254-1 · Cited by 115
Adenosine A2A receptor antagonists: from caffeine to selective non‐xanthines
Jacobson, K. A., Gao, Z., Matricon, P. G., Eddy, M. T., & Carlsson, J. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15103 · Cited by 124
Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human
Jee, H. J., Lee, S. G., Bormate, K. J., & Jung, Y.-S. (2020) · Nutrients · doi:10.3390/nu12103080 · Cited by 111
Transcriptional regulation of human UDP-glucuronosyltransferase genes
Hu, D. G., Meech, R., McKinnon, R. A., & Mackenzie, P. I. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.973037 · Cited by 113
Nutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence?
Boulos, C., Yaghi, N., El Hayeck, R., Heraoui, G. N., & Fakhoury-Sayegh, N. (2019) · Nutrients · doi:10.3390/nu11081896 · Cited by 109
Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease
Camandola, S., Plick, N., & Mattson, M. P. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2492-0 · Cited by 111
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu‐Asia Aging Study
Huang, X., Abbott, R. D., Petrovitch, H., Mailman, R. B., & Ross, G. W. (2008) · Movement Disorders · doi:10.1002/mds.22013 · Cited by 124
Self-citation
Dietary Factors in the Etiology of Parkinson’s Disease
Ağım, Z. S., & Cannon, J. R. (2015) · BioMed Research International · doi:10.1155/2015/672838 · Cited by 115
Health benefits of methylxanthines in neurodegenerative diseases
Oñatibia‐Astibia, A., Franco, R., & Martínez‐Pinilla, E. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600670 · Cited by 110
Neurobiology of Depression and Anxiety in Parkinson's Disease
Kano, O., Ikeda, K., Cridebring, D., Takazawa, T., Yoshii, Y., & Iwasaki, Y. (2011) · Parkinson s Disease · doi:10.4061/2011/143547 · Cited by 107
Environmental factors as modulators of neurodegeneration: Insights from gene–environment interactions in Huntington's disease
Mo, C., Hannan, A. J., & Renoir, T. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.003 · Cited by 108
Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice
Xu, K., Xu, Y., Chen, J., & Schwarzschild, M. A. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00069-1 · Cited by 105
The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk
Tanner, C. M., Goldman, S. M., Ross, G. W., & Grate, S. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.014 · Cited by 119
Self-citation
Risk factors for probable REM sleep behavior disorder
Wong, J. C., Li, J., Pavlova, M. K., Chen, S., Wu, A., Wu, S., & Gao, X. (2016) · Neurology · doi:10.1212/wnl.0000000000002414 · Cited by 103
Association between ambient air pollution and Parkinson's disease: Systematic review and meta-analysis
Hu, C., Fang, Y., Li, F., Dong, B., Hua, X., Jiang, W., Zhang, H., Lyu, Y., & Zhang, X.-J. (2018) · Environmental Research · doi:10.1016/j.envres.2018.10.008 · Cited by 103
The Potential of Spent Coffee Grounds in Functional Food Development
Bevilacqua, E., Cruzat, V. F., Singh, I., Rose’Meyer, R. B., Panchal, S. K., & Brown, L. (2023) · Nutrients · doi:10.3390/nu15040994 · Cited by 121
Pharmacological potential of methylxanthines: Retrospective analysis and future expectations
Monteiro, J., Alves, M. G., Oliveira, P. F., & Silva, B. M. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1461607 · Cited by 104
Smoking and tea consumption delay onset of Parkinson's disease
Kandinov, B., Giladi, N., & Korczyn, A. D. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.02.011 · Cited by 99
Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease
Gyoneva, S., Shapiro, L. P., Lazo, C. R., Garnier‐Amblard, E. C., Smith, Y., Miller, G. W., & Traynelis, S. F. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.004 · Cited by 102
Molecular Mechanisms Controlling the Rate and Specificity of Catechol O-Methylation by Human Soluble Catechol O-Methyltransferase
Lautala, P., Ulmanen, I., & Taskinen, J. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12851-9 · Cited by 96
Parkinsonian signs in older people
Louis, E. D., Luchsinger, J. A., Tang, M. X., & Mayeux, R. P. (2003) · Neurology · doi:10.1212/01.wnl.0000072330.07328.d6 · Cited by 95
Effects of acute caffeine administration on adolescents
Temple, J. L., Dewey, A. M., & Briatico, L. N. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021651 · Cited by 94
A Case-Control Study on Cigarette, Alcohol, and Coffee Consumption Preceding Parkinson’s Disease
Ragonese, P., Salemi, G., Morgante, F., Aridon, P., Epifanio, A., Buffa, D. J., Scoppa, F., & Savettieri, G. (2003) · Neuroepidemiology · doi:10.1159/000071193 · Cited by 96
Pathophysiological roles for purines
Morelli, M., Carta, A. R., Kachroo, A., & Schwarzschild, M. A. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)83010-9 · Cited by 96
Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?
Belvisi, D., Pellicciari, R., Fabbrini, G., Tinazzi, M., Berardelli, A., & Defazio, G. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104671 · Cited by 98
Nongenetic causes of Parkinson’s disease
Chade, A., Kasten, M., & Tanner, C. M. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_23 · Cited by 94
The role of neuroplasticity in dopaminergic therapy for Parkinson disease
Zhuang, X., Mazzoni, P., & Kang, U. J. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.57 · Cited by 92
Chronic Caffeine Treatment Protects Against α-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum
Luan, Y., Ren, X., Zheng, W., Zeng, Z., Guo, Y., Hou, Z., Guo, W. M., Chen, X., Li, F. Y., & Chen, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00301 · Cited by 92
Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB
Yan, R., Zhang, J., Park, H.-J., Park, E. S., Oh, S. E., Zheng, H., Junn, E., Voronkov, M. V., Stock, J. B., & Mouradian, M. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813365115 · Cited by 89
Caffeine in tea Camellia sinensis — Content, absorption, benefits and risks of consumption
Gramza‐Michałowska, A. (2013) · The journal of nutrition health & aging · doi:10.1007/s12603-013-0404-1 · Cited by 92
Adenosine and Related Drugs in Brain Diseases: Present and Future in Clinical Trials
Lopes, L. V., Sebastião, A. M., & Ribeiro, J. A. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795347591 · Cited by 88
Coffee intake and decreased amyloid pathology in human brain
Kim, J. W., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Jung, G., Lee, H. N., Sohn, B. K., Lee, J.-Y., Kim, Y. K., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0604-5 · Cited by 86
Intake of Caffeine and Its Association with Physical and Mental Health Status among University Students in Bahrain
Jahrami, H., Al-Mutarid, M., Penson, P. E., Faris, M. E., Saif, Z., & Hammad, L. (2020) · Foods · doi:10.3390/foods9040473 · Cited by 86
Parkinson's at risk syndrome: Can Parkinson's disease be predicted?
Stern, M. B., & Siderowf, A. D. (2010) · Movement Disorders · doi:10.1002/mds.22719 · Cited by 86
Beneficial and detrimental role of adenosine signaling in diseases and therapy
Liu, H., & Xia, Y. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00350.2015 · Cited by 87
Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment
Siderowf, A. D., & Stern, M. B. (2009) · Annals of Neurology · doi:10.1002/ana.21462 · Cited by 85
Metabolic Syndrome: An Important Risk Factor for Parkinson’s Disease
Zhang, P., & Tian, B. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/729194 · Cited by 86
Neuroprotection by caffeine in the MPTP model of parkinson’s disease and its dependence on adenosine A2A receptors
Xu, K., Luca, D. G. D., Orrù, M., Xu, Y., Chen, J., & Schwarzschild, M. A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.035 · Cited by 84
Impacts of Methylxanthines and Adenosine Receptors on Neurodegeneration: Human and Experimental Studies
Chen, J., & Chern, Y. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_10 · Cited by 85
Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats
Aguiar, L. M. V., Júnior, H. V. N., Macêdo, D. S., Oliveira, A. A., de Freitas, R. M., Vasconcelos, S. M. M., Cunha, G. M. A., de Sousa, F. C. F., & Viana, G. S. D. B. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.05.027 · Cited by 82
Prevention of progression in Parkinson’s disease
Aaseth, J., Dušek, P., & Roos, P. M. (2018) · BioMetals · doi:10.1007/s10534-018-0131-5 · Cited by 83
Novel investigational adenosine A2Areceptor antagonists for Parkinson's disease
Pinna, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903241615 · Cited by 81
The buzz on caffeine in invertebrates: Effects on behavior and molecular mechanisms
Mustard, J. A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1497-8 · Cited by 80
A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease
Dhaenens, C., Burnouf, S., Simonin, C., Brussel, E. V., Duhamel, A., Defebvre, L., Duru, C., Vuillaume, I., Cazeneuve, C., Charles, P., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.009 · Cited by 82
Etiology of Parkinson's Disease
Huang, Z., de la Fuente‐Fernández, R., & Stoessl, A. J. (2003) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710000319x · Cited by 81
Neuroprotective and Anti-inflammatory Properties of a Coffee Component in the MPTP Model of Parkinson's Disease
Lee, K., Im, J., Woo, J. J., Jasutkar, H. G., Kim, Y., Cristóvão, A. C., Sonsalla, P. K., Schuster, D. S., Jalbut, M. M., Fernández, J. R., et al. (2013) · Neurotherapeutics · doi:10.1007/s13311-012-0165-2 · Cited by 78
Dual-Target–Directed Drugs that Block Monoamine Oxidase B and Adenosine A Receptors for Parkinson's Disease
Petzer, J. P., Castagnoli, N. J., Schwarzschild, M. A., Chen, J., & der Schyf, C. J. V. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.035 · Cited by 79
Review article: possible beneficial effects of coffee on liver disease and function
Cadden, I. S., Partovi, N., & Yoshida, E. M. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03319.x · Cited by 77

Authors: Ross, G. W.
Affiliations: United States Department of Veterans Affairs (US)
Corresponding author: Ross, G. Webster
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2000-05-24
Volume: 283
Issue: 20
Pages: 2674
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.283.20.2674
OpenAlex: W2128822428
Cited by: 778
References: 35
Citations by year: 2026: 8 · 2025: 24 · 2024: 28 · 2023: 34 · 2022: 22 · 2021: 39 · 2020: 26 · 2019: 35 · 2018: 26 · 2017: 36 · 2016: 24 · 2015: 29 · 2014: 39 · 2013: 37 · 2012: 36
FWCI: 17.73
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (n01hc005102-027, DAMD17-98-1-8621)
National Institute on Aging (N01‐AG‐4‐2149)
National Heart, Lung, and Blood Institute (N01 HC 05102, NO1-HC-05102)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, coffee consumption, dietary caffeine, caffeine consumption, smoking, nicotinic acid, Honolulu Heart Program, Japanese-American men, disease incidence
MeSH terms: Aged, Caffeine, Coffee, Diet Surveys, Humans, Longitudinal Studies, Male, Middle Aged, Parkinson Disease, Regression Analysis, Risk Factors, Incidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks